Haleon (HLN) FCF Margin (2021 - 2023)

Haleon (HLN) posted FCF Margin of 1.43% for Q4 2023, up 100.41% on a QoQ basis from 347.66% in Q4 2022, and up 34909.0% year-over-year from N/an in Q4 2022.

Haleon (HLN) FCF Margin (2021 - 2023) Analysis & Trends

Haleon's FCF Margin history runs 3 years deep, the most recent figure standing at 1.43% for Q4 2023.

  • Quarterly FCF Margin rose 34909.0% year-over-year to 1.43% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 50.85% (changed N/A YoY) and the FY2025 annual result came in at 20.96%, up 270.0% from the prior year.
  • FCF Margin was 1.43% for Q4 2023 at Haleon, up from 347.66% in the prior quarter.
  • Across five years, FCF Margin topped out at 1.43% in Q4 2023 and bottomed at 347.66% in Q4 2022.
  • A 3-year average of 114.99% and a median of 1.26% in 2021 frame the typical range for FCF Margin.
  • Annual changes were most pronounced in 2022 — FCF Margin slumped 34892 bps — and 2023, when it soared 34909 bps.
  • Haleon's FCF Margin stood at 1.26% in 2021, then plunged by 27698 bps to 347.66% in 2022, then soared by 100 bps to 1.43% in 2023.
  • Business Quant data shows HLN's FCF Margin at 1.43% in Q4 2023, 347.66% in Q4 2022, and 1.26% in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -5.22%
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 12.86%
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -5.35%
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 46.54%
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 9.93%
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 17.73%
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -2.77%
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn 1.04%

Historic Data

Download Data
DateValue
Dec 31, 2023 1.43%
Dec 31, 2022 -347.66%
Dec 31, 2021 1.26%